New in Myeloma
Our "New in Myeloma" articles cover treatment option updates, coverage of advancements from major myeloma academic meetings, and more.
BioLineRx announced the FDA approval of motixafortide to help stem cell mobilization for myeloma patients preparing for transplant.
A myeloma patient shares his insight on wait times for CAR-T Therapy and why it might take some myeloma patients longer than others to get a spot.
A new bi-specific antibody to treat multiple myeloma received U.S. FDA accelerated approval yesterday.
Talquetamab has received its highly anticipated approval to treat multiple myeloma patients.
Researchers at University of Maryland School of Medicine have engineered a new type of CAR T-Cell therapy targeting CD229 on myeloma cells.
Dr. David Coffey, a myeloma specialist and researcher, shared with the myeloma community about his research surrounding single cell sequencing.
A new oral capsule provides innovative myeloma treatment for relapsed/refractory patients.
Stem cell transplants certainly have an effective role in today's myeloma, but what about in the future?
Incredibly impressive results from the Janssen CAR T CARTITUDE-4 study presented at the recent ASCO meeting
Talquetamab is a bi-specific antibody that targets a specific GPRC5D antigen on myeloma cells.